Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: Modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom

Clinical Therapeutics

Volumn 26, Issue 2, 2004, Pages 304-321

  Palmer, Andrew J ^a   Roze, Stéphane ^a   Valentine, William J ^a   Spinas, Giatgen A ^b   Shaw, Jonathan E ^c   Zimmet, Paul Z ^c  

^a IQVIA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Australia; Cost effectiveness; Costs; Diabetes prevention; Diet; Exercise; France; Germany; Metformin; Switzerland; United Kingdom

Indexed keywords

METFORMIN;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; ECONOMICS; FEMALE; FRANCE; GASTROINTESTINAL TOXICITY; GERMANY; GLUCOSE TRANSPORT SYSTEM; HUMAN; LIFE EXPECTANCY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; SWITZERLAND; UNITED KINGDOM;

EID: 1542615736     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90029-X     Document Type: Article

References (75)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med. 1997;14 (Suppl 5):S1-S85.
2. Zimmet R Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.
3. Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health care burden of type 2 diabetes in the UK from 2000 to 2060. Diabet Med. 2002;19(Suppl 4):1-5.
4. Summary of Diabcost statistics. Available at: http.//www.diabetesnsw.com. au/Research/news.asp7NewsID=96. Accessed January 28, 2004.
5. Detournay B, Vauzelle-Kervroedan F, Charles MA, et al. Epidemiology, management and costs of type 2 diabetes in France in 1998 [in French]. Diabetes Metab. 1999;25:356-365.
6. Detournay B, Fagnani F, Pribil C, Eschwege E. Medical resources consumption of type 2 diabetics in France in 1998 [in French]. Diabetes Metab. 2000;26:225-231.
7. Jonsson PM, Marke LA, Nystrom L, et al. Excess costs of medical care 1 and 8 years after diagnosis of diabetes: Estimates from young and middle-aged incidence cohorts in Sweden. Diabetes Res Clin Pract. 2000;50:35-47.
8. Liebl A, Neiss A, Spannheimer A, et al. Costs of type 2 diabetes in Germany. Results of the CODE-2 study [in German]. Dtsch Med Wochenschr. 2001;126:585-589.
9. Jonsson B, for the CODE-2 Advisory Board. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45:S5-S12.
10. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25:829-834.
11. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
12. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
13. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
14. Chiasson JL, Josse RG, Gomis R, et al, for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
15. Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care. 2002;25:2165-2171.
16. Hannover Consensus Group. German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus [in German]. Med Klin (Munich). 2000;95:52-55.
17. Hannoverian Consensus Group. German recommendations for health economic evaluation. Revised edition of the Hannoverian consensus [in German]. Dtsch Med Wochenschr. 1999;124:1503-1506.
18. Detsky AS. Using cost-effectiveness analysis for formulary decision making: From theory into practice. PharmacoEconomics. 1994;6:281-288.
19. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992; 146: 473-481.
20. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ. 1993;306:570-572.
21. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-1341.
22. US Dept of Health and Human Services. Public Health Service. Cost Effectiveness in Health and Medicine. Washington, DC: US Government Printing Office; 1996.
23. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
24. Guide to the technology appraisal process. National Institute for Clinical Excellence Web site. Available at: http://www.nice.org.uk/pdf/ technologyappraisal-processfinal.pdf. Accessed July 4, 2002.
25. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Available at: http://www.health.gov.au/pbs/pharm/pubs/guidelines/index.htm. Accessed January 28, 2004.
26. Sullivan SD, Lyles A, Luce B, et al. AMCP guidelines for submission of clinical and economic evaluation data to support formulary listing in the US health plans and pharmacy benefits management organizations. J Manag Care Pharm. 2001;7:272-282.
27. Detsky AS, Naglie G, Krahn MD, et al. Primer on medical decision analysis: Part 1 - getting started. Med Decis Making. 1997;17:123-125.
28. Detsky AS, Naglie G, Krahn MD, et al. Primer on medical decision analysis: Part 2 - building a tree. Med Decis Making. 1997;17:126-135.
29. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making. 1993;13:322-338.
30. Naimark D, Krahn MD, Naglie G, et al. Primer on medical decision analysis: Part 5 - working with Markov processes. Med Decis Making. 1997;17:152-159.
31. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. PharmacoEconomics. 1998;13:397-409.
32. Palmer AJ, Roze S. Prevention of type 2 diabetes in the USA: Cost effectiveness issues. Val Health. 2002;5:204. Abstract.
33. Palmer AJ, Roze S. Cost effectiveness issues in type 2 diabetes prevention in the USA. Diabetes. 2002;51: A279. Abstract.
34. Palmer AJ, Roze S. Improvements in life expectancy with lifestyle changes or metformin in overweight, glucose intolerant patients: Modeling the long term implications of the Diabetes Prevention Program. Diabetes. 2002;51:A420. Abstract.
35. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20:735-744.
36. Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for type I diabetes: A Swiss perspective. Diabetologio, 2000;43:13-26.
37. Palmer AJ, Brandt A, Gozzoli V, et al. Outline of a diabetes disease management model: Principles and applications. Diabetes Res Clin Pract. 2000;50(Suppl 3):S47-S56.
38. Brown JB, Palmer AJ, Bisgaard P, et al. The Mt. Hood challenge: Cross-testing two diabetes simulation models. Diabetes Res Clin Pract. 2000;50(Suppl 3):S57-S64.
39. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ. 2000;320:1373-1378.
40. Clarke P, Gray A, Adler A, et al. Cost effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia. 2001;44:298-304.
41. Gozzoli V, Palmer AJ, Brandt A, et al. Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients [in German]. Dtsch Med Wochenschr. 2000;125:1154-1159.
42. Life tables for 191 countries. World mortality in 2000. World Health Organization Web site. Available at: http://www3.who.int/whosis/life_tables/ life_tables.cfm?path=evidence,life_tables&language=english. Accessed December 7, 2003.
43. Eriksson J, Lindstrom J, Valle T, et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: The Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diobetologia. 1999;42:793-801.
44. Eriksson KF, Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia. 1998;41:1010-1016.
45. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care. 1998;21:1138-1145.
46. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care. 2001;24:447-453.
47. Shaw JE, Hodge AM, de Courten M, et al. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia. 1999;42:1050-1054.
48. Harris MI, Klein R, Welborn TA, Knuiman MW Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15:815-819.
49. Thompson TJ, Engelgau MM, Hegazy M, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med. 1996; 13:337-340.
50. Doctors' Schedule of Fees [in German]. Bern, Switzerland: Federal Department of the Interior; 2000.
51. Medicare Benefits Schedule, 1 November 2001, including 1 May 2002 Supplement. Available at: http:// www.health.gov.au/pubs/mbs/mbs7/introduc.html. Accessed January 28, 2004.
52. Schedule of pharmaceutical benefits. Effective from 1 November 2003. Available at: http://wwwl.health.gov.au/pbs/scripts/search.cfm. Accessed January 28, 2004.
53. IMS Health Web site. Available at: http://www imshealth.com. Accessed July 17, 2002.
54. Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: Incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care. 2000;23:1654-1659.
55. Guidelines for Economic Evaluation of Therapeutic Strategies [in French]. Paris, France: French Health Economists Association; 1997.
56. Federal Office of Social Insurance. Manual for the Standardization of Clinical and Economic Evaluation of Medical Technology [in German]. Bern, Switzerland: Swiss Office of Social Security; 1998.
57. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care. 2000;23:390-404.
58. Saydah SH, Miret M, Sung J, et al. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care. 2001;24:1397-1402.
59. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: What is a clinically significant gain? J Gen Intern Med. 1994;9:702-707.
60. Detsky AS, Redelmeier DA. Measuring health outcomes - putting gains into perspective. N Engl J Med. 1998;339:402-404.
61. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med. 1998;339:380-386.
62. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-390.
63. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
64. Shaw JE, Chisholm DJ. I: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome [published correction appears in Med J Aust. 2003;179: 526]. Med J Aust. 2003;179:379-383.
65. DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26:61-69.
66. Diabetes Prevention Program Resarch Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
67. Watanabe M, Yamaoka K, Yokotsuka M, Tango T. Randomized controlled trial of a new dietary education program to prevent type 2 diabetes in a high-risk group of Japanese male workers. Diabetes Care. 2003; 26:3209-3214.
68. Wenying Y, Lixiang L, Jinwu Q, et al. The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: A 3 year multicenter prospective study. Chin J Endocrinol Metab. 2001;17:131-136.
69. Torgerson JS, Arlinger K, Kappi M, Sjostrom L. Principles for enhanced recruitment of subjects in a large clinical trial. The XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. Control Clin Trials. 2001;22:515-525.
70. Scheen AJ. Info-congress. Prevention of type 2 diabetes in obese patients: First results with orlistat in the XENDOS study [in French]. Rev Med Liege. 2002;57:617-621.
71. National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
72. Herman WH, Alexander CM, Cook JR, et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care. 1999;22:1771-1778.
73. Jönsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial. Diabetologia. 1999;42:1293-1301.
74. Slama G. The potential of metformin for diabetes prevention. Diabetes Metab. 2003;29:6S104-6S111.
75. Ziegler O, Simon C. French diabetologists' standpoint on the prevention of type 2 diabetes. A survey carried out during the ALFEDIAM Convention Bordeaux 2003 [in French]. Diabetes Metab. 2003;29:307-314.